GlassScriptPhysician profile
Payman Sattar
NPI 1780609057
$9,124.45
in general payments reported to CMS, 2019-2025
26 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $539 · 2021: $1,178 · 2022: $2,651 · 2023: $538 · 2024: $1,326 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,200 · Food and Beverage: $778 · Consulting Fee: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,200.00 |
| Food and Beverage | $777.70 |
| Consulting Fee | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $3,497.40 | 2021-2023 | Indigo System |
| Chiesi USA, INC. | $1,200.00 | 2024 | Juxtapid |
| Boston Scientific Corporation | $1,116.36 | 2019-2024 | Avvigo Guidance System |
| Abiomed | $547.35 | 2020-2023 | Impella |
| Endologix LLC | $539.98 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $452.97 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $386.69 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $223.12 | 2019 | |
| Abbott Laboratories | $213.61 | 2020-2021 | |
| Amgen INC. | $157.59 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $141.72 | 2019-2024 | Xarelto |
| Medtronic, INC. | $115.06 | 2021-2025 | Sprinter Legend, Surgipro Ll |
| Philips North America LLC | $114.24 | 2019 | |
| Cardiovascular Systems INC. | $113.19 | 2019 | |
| Merck Sharp & Dohme LLC | $52.68 | 2025 | Verquvo, Capvaxive |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $49.29 | 2019 | |
| W. L. Gore & Associates, INC. | $34.19 | 2019 | |
| Shockwave Medical, INC | $28.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.47 | 2025 | |
| Ekos Corporation | $19.67 | 2019 | |
| Inari Medical, INC. | $19.17 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2024 | Jardiance |
| Astellas Pharma US INC | $16.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.51 | 2021 | |
| Cardinal Health 200 LLC | $15.18 | 2019 | |
| Terumo Medical Corporation | $14.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$160.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payman Sattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.